Detalhe da pesquisa
1.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Blood
; 130(10): 1198-1204, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684537
2.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Blood
; 121(9): 1517-23, 2013 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23297129
3.
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Mayo Clin Proc
; 81(8): 1047-53, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16901028
4.
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Clin Cancer Res
; 10(24): 8170-6, 2004 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15623591